← Eichor
Study identifier: NCT06696534 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Exploring Participant Preference for Screening Methods and Experience Into Colorectal Cancer Screening Programme

Condition: Screening for Colon Cancer · Survey and Questionnaire  ·  Sponsor: ADVANCED MARKER DISCOVERY S.L.

PhaseNA
Planned participants1000
Who can joinAll sexes, 50 Years to 69 Years
Healthy volunteersYes

About this study

The goal of this low-risk interventional study is to analyze participants' assessment of colorectal cancer screening program through screening method preference and experience after FOBT analysis in screaned participant population for colorectal cancer; could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to answer are: * Values of experience of participants into screening programme. * Values of preferences of participants for screening methods. Participants will answer two questionnaires and they'll be given their information and clinical data to investigator or health personnel.

This description comes directly from the study's public registry record.

Talk to the study team

Marta Jimenez, PhD  ·  +34 637899149  ·  mjimenez@amadix.com

Always discuss trial participation with your own doctor first.

Locations (2)

UCSP Sete RiosLisbon, PortugalNot Yet Recruiting
CS Mar BálticoMadrid, Madrid, SpainRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06696534